Decreased survival in hepatitis C patients with monomorphic post-transplant lymphoproliferative disorder after liver transplantation treated with frontline immunochemotherapy

References

• Dharnidharka VR, Webster AC, Martinez OM, et al. Post-transplant lymphoproliferative disorders. Nat Rev Dis Primers. 2016;2:15088.
   PubMed Web of Science ®Google Scholar
• Al-Mansour Z, Nelson BP, Evens AM. Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies. Curr Hematol Malig Rep. 2013;8:173–183.
   PubMed Web of Science ®Google Scholar
• Choquet S, Leblond V, Herbrecht R, et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood. 2006;107:3053–3057.
   PubMed Web of Science ®Google Scholar
• Evens AM, David KA, Helenowski I, et al. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol. 2010;28:1038–1046.
   PubMed Web of Science ®Google Scholar
• Kamdar KY, Rooney CM, Heslop HE. Posttransplant lymphoproliferative disease following liver transplantation. Curr Opin Organ Transplant. 2011;16:274–280.
   PubMed Web of Science ®Google Scholar
• Trappe RU, Dierickx D, Zimmermann H, et al. Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful stratification into rituximab or R-CHOP consolidation in an international, prospective, multicenter phase II trial. J Clin Oncol. 2017;35:536–543. 2016
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–2390.
   PubMed Web of Science ®Google Scholar
• Ferreiro JF, Morscio J, Dierickx D, et al. EBV-positive and EBV-negative posttransplant diffuse large B cell lymphomas have distinct genomic and transcriptomic features. Am J Transplant. 2016;16:414–425.
   PubMed Web of Science ®Google Scholar
• Norin S, Kimby E, Ericzon BG, et al. Posttransplant lymphoma-a single-center experience of 500 liver transplantations. Med Oncol. 2004;21:273–284.
   PubMed Web of Science ®Google Scholar
• Leblond V, Dhedin N, Mamzer Bruneel MF, et al. Identification of prognosis factors in 61 patients with posttransplantation lymphoproliferative disorders. J Clin Oncol. 2001;19:772–778.
   PubMed Web of Science ®Google Scholar
• Leblond V, Davi F, Charlotte F, et al. Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity? J Clin Oncol. 1998;16:2052–2059.
   PubMed Web of Science ®Google Scholar
• Reshef R, Vardhanabhuti S, Luskin MR, et al. Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder. Am J Transplant. 2011;11:336–347.
   PubMed Web of Science ®Google Scholar
• Swinnen LJ, LeBlanc M, Grogan TM, et al. Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder. Transplantation. 2008;86:215–222.
   PubMed Web of Science ®Google Scholar
• Oertel SH, Verschuuren E, Reinke P, et al. Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant. 2005;5:2901–2906.
   PubMed Web of Science ®Google Scholar
• Choquet S, Trappe R, Leblond V, et al. CHOP-21 for the treatment of post-transplant lymphoproliferative disorders (PTLD) following solid organ transplantation. Haematologica. 2007;92:273–274.
   PubMed Web of Science ®Google Scholar
• Dierickx D, Cardinaels N. Posttransplant lymphoproliferative disorders following liver transplantation: where are we now? World J Gastroenterol. 2015;21:11034–11043.
   PubMed Web of Science ®Google Scholar
• Patel H, Vogl DT, Aqui N, et al. Posttransplant lymphoproliferative disorder in adult liver transplant recipients: a report of seventeen cases. Leuk Lymphoma. 2007;48:885–891.
   PubMed Web of Science ®Google Scholar
• McCarthy M, Ramage J, McNair A, et al. The clinical diversity and role of chemotherapy in lymphoproliferative disorder in liver transplant recipients. J Hepatol. 1997;27:1015–1021.
   PubMed Web of Science ®Google Scholar
• Ben-Ari Z, Amlot P, Lachamanan SR, et al. Posttransplantation lymphoproliferative disorder in liver recipients: characteristics, management, and outcome. Liver Transpl. 2003;5:184–191.
   Google Scholar
• Nelson BP, Nalesnik M, Bahler DW, et al. Epstein-Barr virus-negative post-transplant lymphoproliferative disorders. A distinct entity? Am J Clin Pathol. 2000;24:375–385.
   Google Scholar
• Gulley ML, Tang W. Laboratory assays for Epstein-Barr virus-related disease. J Mol Diagn. 2008;10:279–292.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–586.
   PubMed Web of Science ®Google Scholar
• Abrey LE. Primary central nervous system lymphoma. Curr Opin Neurol. 2009;22:675–680.
   PubMed Web of Science ®Google Scholar
• Marino D, Burra P, Boccagni P, et al. Post-transplant lymphoproliferative disorders in liver transplanted patients: a single-centre experience. Anticancer Res. 2010;30:2383–2391.
   PubMed Web of Science ®Google Scholar
• Trappe R, Oertel S, Leblond V, et al. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol. 2012;13:196–206.
   PubMed Web of Science ®Google Scholar
• Kawatani T, Suo T, Tajima F, et al. Incidence of hepatitis virus infection and severe liver dysfunction in patients receiving chemotherapy for hematologic malignancies. Eur J Haematol. 2001;67:45–50.
   PubMed Web of Science ®Google Scholar
• Ennishi D, Maeda Y, Niitsu N, et al. Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis. Blood. 2010;116:5119–5125.
   PubMed Web of Science ®Google Scholar
• Ennishi D, Terui Y, Yokoyama M, et al. Monitoring serum hepatitis C virus (HCV) RNA in patients with HCV-infected CD20-positive B-cell lymphoma undergoing rituximab combination chemotherapy. Am J Hematol. 2008;83:59–62.
   PubMed Web of Science ®Google Scholar
• Pozzato G, Mazzaro C, Dal Maso L, et al. Hepatitis C virus and non-Hodgkin's lymphomas: meta-analysis of epidemiology data and therapy options. World J Hepatol. 2016;8:107–116.
   PubMedGoogle Scholar
• Peveling-Oberhag J, Arcaini L, Hansmann ML, et al. Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management. J Hepatol. 2013;59:169–177.
   PubMed Web of Science ®Google Scholar
• Turner NC. Hepatitis C and B-cell lymphoma. Ann Oncol. 2003;14:1341–1345.
   PubMed Web of Science ®Google Scholar
• Morgensztern D, Rosado M, Silva O, et al. Prevalence of hepatitis C infection in patients with non-Hodgkin’s lymphoma in South Florida and review of the literature. Leuk Lymphoma. 2004;45:2459–2464.
   PubMed Web of Science ®Google Scholar
• Morton LM, Landgren O, Chatterjee N, et al. Hepatitis C virus infection and risk of posttransplantation lymphoproliferative disorder among solid organ transplant recipients. Blood. 2007;110:4599–4605.
   PubMed Web of Science ®Google Scholar
• Borchardt RA, Torres HA. Challenges in managing hepatitis C virus infection in cancer patients. World J Gastroenterol. 2014;20:2771–2776.
   PubMedGoogle Scholar
• Liang TJ, Ghany MG. Current and future therapies for hepatitis C virus infection. N Engl J Med. 2013;368:1907–1917.
   PubMed Web of Science ®Google Scholar
• Burstow NJ, Mohamed Z, Gomaa AI, et al. Hepatitis C treatment: where are we now? Int J Gen Med. 2017;10:39–52.
   PubMed Web of Science ®Google Scholar
• Economides MP, Mahale P, Kyvernitakis A, et al. Concomitant use of direct-acting antivirals and chemotherapy in hepatitis C virus-infected patients with cancer. Aliment Pharmacol Ther. 2016;44:1235–1241.
   PubMed Web of Science ®Google Scholar
• Curry MP. Direct acting antivirals for decompensated cirrhosis. Efficacy and safety are now established. J Hepatol. 2016;64:1206–1207.
   PubMed Web of Science ®Google Scholar
• Gane EJ, Agarwal K. Directly acting antivirals (DAAs) for the treatment of chronic hepatitis C virus infection in liver transplant patients: “a flood of opportunity”. Am J Transplant. 2014;14:994–1002.
   PubMed Web of Science ®Google Scholar
• Torres HA, Chong PP, De Lima M, et al. Hepatitis C virus infection among hematopoietic cell transplant donors and recipients: American Society for Blood and Marrow Transplantation task force recommendations. Biol Blood Marrow Transplant. 2015;21:1870–1882.
   PubMed Web of Science ®Google Scholar